Thus, targeting MARCH-1 in monocytes/macrophages could represent a new autologous cell-based therapies strategy for inducing anti-inflammatory conditions such as cerebral palsy, arthrosynovitis, diabetic wound, atherosclerosis and so on. Here, MARCHF1 is linked to atherosclerosis.